The Pas1 locus is the major tumor modifier of lung tumorigenesis in mouse inbred strains. Of six genes contained in a conserved haplotype, three (Casc1, Kras and Ifltd1) have been proposed as Pas1 candidates, but mechanistic evidence is sparse. Herein, we examined urethane-induced lung tumorigenesis in a new mouse model developed by replacing the Kras gene with an Hras gene in the susceptible A/J-type Pas1 locus and crossing these mice with either C57BL/6J or A/J mice. Heterozygous mice carrying the Hras-replacement gene were more susceptible than wild-type mice to lung carcinogenesis, indicating that Hras replacement not only compensates for Kras functions, but is more active. Indeed, most lung tumors carried a Gln61Leu mutation in the Hras-replacement gene, whereas no mutations were observed in the endogenous Hras gene. Thus, the context of the Kras locus determined mutability of ras genes. In mice carrying the Hras-replacement gene, the mutation frequency affecting the wild-type Kras gene was much higher when this gene was located in the A/J type than in the C57BL/6J-type Pas1 locus (12 versus 0%, Àlog P ¼ 5.0). These findings identify cis-acting elements in the Pas1 locus as the functional components controlling genetic susceptibility to lung tumorigenesis by modulating mutability of the Kras gene.
Introduction
The Pas1 locus affects inherited predisposition to both chemically induced and spontaneous lung tumorigenesis in laboratory mouse inbred strains (Manenti and Dragani, 2005) . Linkage disequilibrium analyses indicate a complex multigenic nature of the Pas1 locus, pointing to a functional role for both intronic and exonic polymorphisms of six genes contained in the Pas1-conserved haplotype (Manenti et al., 2004) . Among these six genes, Las1 (also called Casc1), Kras and Ifltd1 (also called Pas1c1 and Lmna-rs1) have all been proposed as candidates for the Pas1 locus, but the functional elements responsible for the high inherited susceptibility to lung tumorigenesis have not yet been identified. Previous analyses have suggested that Kras modulates only lung tumor progression by unknown functional polymorphisms that affect allele-specific expression of activated Kras protein in lung tumors, whereas Casc1 coding polymorphisms are expected to modulate lung tumor multiplicity (Zhang et al., 2003) . Although a differential effect of Ifltd1 on tumor cell proliferation has been proposed based on the strainspecific isoforms of this gene (Wang et al., 2005) , the candidacy of Ifltd1 based on such a mechanism of action seems unlikely as the gene is not expressed in lung tumors (Manenti et al., 2004) . Most recently , Kras gene candidacy for the Pas1 locus has been proposed based on a mechanism involving the balance between the expression levels of Kras wild-type and mutant alleles in lung tumor cells, although the element(s) determining the differential expression levels of Kras remain unknown . Among the three members of the ras gene family, Kras is essential for normal mouse development because Kras-deficient embryos die before term (Johnson et al., 1997; Koera et al., 1997) . A knock-in model where the Hras coding sequence replaced the Kras gene at the Kras locus, being therefore under the control of the same regulatory sequences of the Kras gene, showed that the Hras geneencoded protein may replace the Kras function, as mice homozygous for the Hras-replacement cassette were viable, although they showed a cardiovascular pathology in adult mice (Potenza et al., 2005) .
To obtain further insight into the role of wild-type Kras in lung tumorigenesis and the relationships between Kras, its flanking sequences, and Pas1 locus functions, we analysed urethane-induced lung tumorigenesis in mice carrying the Hras cassette in the 129Sv background (Potenza et al., 2005) and crossed with either the lung tumor-susceptible A/J strain or the resistant C57BL/6J strain. Our results indicate a role for the genomic milieu of the Pas1 locus in controlling Pas1 function through the modulation of Kras mutability.
Results
Kras/Hras heterozygous mice are highly susceptible to lung tumorigenesis Crosses of Kras/Hras heterozygous mice with wild-type Kras homozygous mice produced progeny at the expected Mendelian ratio of about 50% heterozygous Kras/Hras mice and 50% Kras homozygous mice (Figure 1) . Thus, Kras/Hras heterozygosity at the Kras locus did not affect mouse viability in both crosses. Incidence of lung tumors induced by urethane treatment was almost 100% in all groups. Because analysis of lung tumor multiplicity revealed no significant overall sex differences, results of male and female mice were grouped together.
The total number of lung tumors was highly dependent on either the genetic cross or the Kras allele status. Indeed, in the C57BL/6J cross, Kras homozygous and Kras/Hras heterozygous mice developed 6.5±0.3 (n ¼ 92) and 18.8±0.6 (n ¼ 90) (mean±s.e.) lung tumors, respectively; in the A/J cross, Kras homozygous and Kras/Hras heterozygous mice developed 17.0±0.7 (n ¼ 73) and 26.2±0.8 (n ¼ 70) (mean±s.e.) lung tumors, respectively (Figure 2 ). Statistical analysis indicated a strong effect of the Kras locus genotype Figure 1 Schematic of crosses between heterozygous Kras/Hras mice on a 129Sv genetic background and either A/J (a) or C57BL/ 6J (b) mice. In both experimental crosses, a group carrying Kras/ Hras heterozygosity (left) at the Kras locus is compared with a Kras/Kras wild-type group (right). Mice heterozygous for the Kras and the Hras allele at the Kras locus were maintained in the 129Sv genetic background (Potenza et al., 2005) . In Naples laboratory, F1 hybrids between Kras/Hras mice and either C57BL/6J or A/J mice were generated by in vitro fertilization. Briefly, male Kras/Hras mice were anesthetized and killed by cervical dislocation. Sperm was collected from the vasa deferentia and cauda epididymis, diluted in 1 ml of M16 (Sigma) and kept at 37 1C for 30 min. Sperm sample (40 ml) was then added to a 250-ml drop of M16 medium (fertilization drop) and covered with light mineral oil (Sigma, St Louis, MO, USA). Prepubertal female A/J or C57BL/6J mice (from Harlan Italy, Udine, Italy) were superovulated by intraperitoneal (i.p.) injections with 5 IU of pregnant mare serum gonadotropin (PMSG; Sigma) and, after 48 h, 5 IU of human chorionic gonadotropin (hCG; Sigma). About 14 h later, oocytes were collected from the oviducts, treated with 0.1% hyaluronidase, washed with M16 medium and added to the fertilization drop (oocytes from five superovulated female mice to each fertilization drop). After incubation for 5 h at 37 1C in a 5% CO 2 incubator, fertilized oocytes were washed with M16 medium and cultured overnight in a 250-ml fresh drop of M16 medium. The next day, the resulting embryos were transferred into pseudo-pregnant females for fostering. Figure 2 Kras allele status and genetic cross affect lung tumor multiplicity (top) and multiplicity of large (>2 mm in diameter) tumors (bottom). Continuous and red lines represent the C57BL/6J and the A/J cross, respectively. Number of differences between crosses (Àlog P ¼ 32) or between Kras locus genotypes (Àlog P ¼ 29) are highly statistical significant. Mice were shipped to Milan, where male and female mice of the C57BL/6J cross (n ¼ 182) or of the A/J cross (n ¼ 143) mice were injected i.p. with urethane (BDH, Poole, UK) dissolved in water (1000 mg/kg body weight); mice were injected without previous knowledge of their Kras locus allele status. All mice of the C57BL/6J cross were treated at 4-5 weeks of age, whereas 50% of the mice of the A/J cross were treated between 4 and 7 weeks of age and the remaining 50% were treated between 7 and 12 weeks of age, due to problems in the in vitro fertilization and shipping of the animals. Mice were maintained without any further treatment for 30 weeks after urethane injection, when all mice were killed. Lungs were perfused, removed and immersed in buffered 10% formalin solution. Tumors >0.3 mm diameter (detection limit) on the lung surface were counted after tissue fixation, and tumor size was measured. Selected lung sections were stained with hematoxylin and eosin for histological analysis. Experiments have been approved by our internal ethical committee. Differences between groups in lung tumor multiplicity (N), number of tumors >1.0 (N>1) or 2.0 mm (N>2) in diameter were evaluated by the general linear model (GLM) analysis of variance. Correlations between N, N>1 and N>2 values were analysed using the Spearman's rank correlation test.
Pas1 modulates Kras mutability G Manenti et al (Kras/Kras versus Kras/Hras, Àlog P ¼ 52) and of the genetic cross (A/J versus C57BL/6J, Àlog P ¼ 40). Large tumors were detected mostly in Kras/Hras heterozygous mice, with 68 of 70 (97%) in the A/J cross and 44 of 90 (49%) in the C57BL/6J cross, showing lung tumors larger than 2 mm in diameter. In Kras/Kras wildtype mice, these large tumors were observed in 39 of 73 (53%) and in 1 of 92 (1%) mice of the A/J and the C57BL/6J cross, respectively. In the C57BL/6J cross, Kras homozygous and Kras/Hras heterozygous mice developed 0.0±0.0 and 1.0±0.2 lung tumors >2 mm in diameter, respectively; in the A/J cross, Kras homozygous and Kras/Hras heterozygous mice developed 1.2±0.2 and 5.3±0.4 lung tumors >2 mm in diameter, respectively (Figure 2) . A highly significant difference in large tumor multiplicity was observed for both Kras allele status (Àlog P ¼ 29) and genetic cross (Àlog P ¼ 32) (Figure 2 ).
ras Genes in the Pas1 susceptible allele became highly mutable in lung tumors Lung tumors from wild-type and Kras/Hras heterozygous mice were analysed for mutations of endogenous Hras and Kras genes, as well as of the Hras-replacement gene, at codons 12-13 and 61, that is, the common targets of mutations. In no cases mutations at codons 12-13 were detected. In wild-type mice of the A/J cross, no mutations were detected in codon 61 of the endogenous Hras gene (Table 1) . The Hras-replacement gene was, however, highly mutated in Kras/Hras mice of both crosses. Indeed, such mutations were detected in 131/151 (87%) of tumors derived from 38 mice of the A/ J cross and in all 128 tumors from 39 mice of the C57BL/6J cross (Àlog P ¼ 5.3; Table 1 ). Most of the Hras-replacement gene mutations (that is, 128/131 and 127/128 in A/J and C57BL/6J cross, respectively) consisted in a CAA-CTA (Gln61Leu) change. A high frequency of Kras mutations was detected in wild-type mice of the A/J cross (total of 66 mutations in 83 tumors, 80%; Table 1 ). Similarly, in wild-type mice of the C57BL/6J cross, a high frequency of Kras mutations was detected (76/88, 86%; Table 1 ). In Kras/Hras heterozygous mice, Kras mutations were found in 18/ 151 (12%) tumors of the A/J cross, but in none of the 128 tumors from C57BL/6J cross and this difference was statistically significant (Àlog P ¼ 5.0; Table 1 ). Of these 18 Kras mutations, 17 consisted in a CAA-CGA (Gln61Arg) change, whereas one case represented a and 5 0 -ggctgtttagatcaacaagctaaat-3 0 . Nucleotide sequence analysis of exon 2 of the Kras gene was carried out by PCR amplification of the genomic fragment specific for the wild-type allele using PCR primers: 5 0 -gccacttgtctgctttggag-3 0 and 5 0 -tcatgcaggcataacaattagc-3 0 , or for the Hrasreplacement gene using primers: 5 0 -ccagactgtgtttctcccttc-3 0 and 5 0 -ccattggcacatcatctgaa-3 0 . Exon 2 of endogenous Hras was amplified and sequenced using PCR primers: 5 0 -cccactaagccgtgttgttt-3 0 and 5 0 -tggtgttgttgatggcaaat-3 0 . PCR reactions contained 1 Â buffer Taq Gold (Applied Biosystems, Foster City, CA, USA), 1.5 mM MgCl 2 , 200 mM dNTPs, 5 pmol of each primer, 1 U Taq Gold (Applied Biosystems) and 30 ng genomic DNA in a total volume of 25 ml. Frequencies of Hras and Kras mutations in different genotype groups were analyzed using the Fisher's exact test. Pas1 modulates Kras mutability G Manenti et al CAA-CTA change. The presence of a Kras or Hras-replacement mutation was mutually exclusive, with no tumors containing mutation in both genes.
Expression of Kras and Hras genes in normal lung and in lung tumors
We quantitatively evaluated relative mRNA expression of wild-type Kras and of the Hras-replacement gene at the Kras locus. In normal lung tissue from Kras/Hras mice, specific transcripts of either gene were expressed at similar levels, as determined by both pyrosequencing analysis and by counting individual recombinant clones. A count of 302 full-length clones indicated a very similar frequency of Kras-(52%) and Hras (48%)-specific mRNA transcripts, in agreement with pyrosequencing results (Figure 3) . Analysis of mRNA expression in lung tumors was carried out only by counting recombinant clones, because RNA amounts extracted from tumor tissue was insufficient for pyrosequencing analysis. In tumors with Kras mutations, 40 and 60% of 124 clones belonged to Kras and Hras transcripts, respectively (Figure 3 ). In tumors with Hras mutations, 44 and 56% of 347 clones belonged to Kras and Hras transcripts, respectively (Figure 3) . Thus, similar expression levels of the two transcripts were detected in both normal and tumor tissues.
Discussion
Kras mutations are frequently observed in either spontaneous or chemically induced mouse lung tumors . Lung tissue expression of mutated Kras (Meuwissen et al., 2001) or spontaneous Kras activation in vivo (Johnson et al., 2001) in the mouse confers a high susceptibility to lung tumorigenesis, suggesting that Kras mutations in lung epithelial cells represent causal determinants of lung tumors in mice.
Here we show that mutability of ras genes in lung tumors depends on their genetic context. Indeed, although the same proteins were encoded by the endogenous and the replacement Hras genes, the endogenous Hras gene was not mutated in any tumors, whereas the Hras-replacement gene in the Kras locus was frequently mutated. Because conservation of the Pas1 haplotype in mouse inbred strains (Manenti et al., 2004) ensures that the Hras-replacement gene inserted into the 129Sv genetic background of Embryonic stem cell is flanked by the same genetic elements as in the A/J and other Pas1 susceptibility allele carrier strains, genetic elements in Pas1 controlling Kras gene mutability would be expected to result in both Hras and Kras mutations at equal frequency in tumors originated from the A/J cross. On the other hand, Hras replacement but not Kras mutations are expected in the C57BL/ 6J cross in which the Hras-replacement gene is flanked by Pas1-susceptible allele genetic elements but Kras and its flanking elements derive from the C57BL/6J (Pas1 allele resistance) strain. In the C57BL/6J cross, we in fact observed 100% mutation frequency in the Hrasreplacement gene and no Kras mutation. In the A/J cross, Kras gene mutations were observed but at a lower frequency than the 1:1 ratio of Hras:Kras mutations predicted (Table 1 ). The deviation from the predicted frequency may rest in the higher tumorigenic potential of Hras than Kras mutations. Indeed, mutation frequency of Kras was highly dependent on its cis-acting genome background (Àlog P ¼ 5.0), with 0% (C57BL/6J cross) versus 12% (A/J cross) Kras mutation frequency observed.
Our findings point to the importance of both Kras and Hras in lung tumorigenesis. Consistent with this notion, the transgenic mouse line rasH2 carrying three copies of the normal human Hras gene develops lung tumors at Figure 3 Relative transcript abundance of Kras-and Hrascassette genes in normal lung tissue and in lung tumors with mutations at either Kras or Hras genes, in Kras/Hras heterozygous mice. Values represent mean percentages ± s.e. of Kras clones from 3 to 5 samples per group; thus, mean percentages of Hras clones are the complement to 100 of the Kras values. Normal lungs were excised from adult (4-months old) male A/J, C57BL/6J, 129/Sv and Kras/Hras mice. Lung tumors were excised from mice of the A/J cross (either heterozygous or homozygous for the Kras allele) and frozen at À80 1C. Total RNA was extracted from normal lung of A/J, C57BL/6J, 129/Sv and Kras/Hras mice, or from lung tumors using RNeasy Midi Kit (Qiagen) or RNAeasy Mini kit (MachereyNagel, Duren, Germany). Total RNA (100 ng) was retro-transcribed using SuperScript III First-Strand Synthesis System for reverse transcription (RT)-PCR (Invitrogen, Carlsbad, CA, USA). To quantitatively evaluate the relative expression of wild-type Kras and of the Hras-replacement gene at the Kras locus, we developed a method that uses a polymorphism within closely related mRNA sequences as an allele-specific tag. Kras-and Hras-replacement sequences were PCR-amplified from cDNA by the same oligonucleotide pair (5 0 -ggagagaggcctgctgaaa-3 0 , 5 0 -aagtgtgccttaagaaagagtacaaa-3 0 ), followed by pyrosequencing using a PSQ HS96A instrument (Biotage AB, Uppsala, Sweden) to measure genespecific transcript levels. A sequencing primer (5 0 -gatgccttctataca-3 0 ) was designed in a sequence trait showing 100% identity in both transcripts and located just ahead of a T/C nucleotide change that was genotyped as a polymorphism able to distinguish the mRNA deriving from the Kras (T allele) or the Hras-replacement gene (C allele). The allele-specific signals in the pyrogram are related to the relative quantities of the Kras-and Hras-replacement gene mRNAs. The wild-type Hras gene is not amplified in this procedure because the PCR primers are highly specific for the model under investigation. We also used a method based on the count of clones specific for either transcript. Clones were obtained by PCR amplification of Kras and Hras transcripts, using the same common PCR primers used for pyrosequencing amplification, followed by subcloning into pGEM T easy Vector System (Promega, Madison, WI, USA), PCR amplification of Kras-or Hras-specific sequences from the DNA of the cloned recombinant plasmids, and confirmation by nucleotide sequencing.
Pas1 modulates Kras mutability G Manenti et al high incidence after treatment with several chemical carcinogens, including urethane (Umemura et al., 1999) . Lung tumors induced by urethane in this rasH2 transgenic model show a high frequency of mutations at codon 61 of the Hras transgene (Tomisawa et al., 2003) , as well as mutations in the endogenous Kras gene (Ogawa et al., 1996) . Another transgenic mouse, which carries the mutated human Hras gene driven by the albumin enhancer/promoter, spontaneously develops numerous lung neoplasms as early as 2 months of age, suggesting the potency of mutated Hras in the development of mouse lung tumors (Maronpot et al., 1991) . Mutated Hras has also been reported to be more potent than mutated Kras in mediating tumorigenic transformation of fibroblasts (Maher et al., 1995) . This higher tumorigenic potential of mutated Hras than Kras may account for the higher growth rate (larger size) of lung tumors in our Kras/Hras heterozygous mice and for the high frequency of tumors harboring Hras mutations. Our results are in accord with previous studies of mouse lung tumors indicating the preferential mutability of the Kras allele carried by the A/J strain over the allele carried by the C57BL/6J strain (You et al., 1992; Manenti et al., 1995) . However, in those studies it was not possible to determine whether the allele-specific Kras mutability was due to trans-or to cis-acting elements; indeed, these effects have been attributed to differential mRNA expression of the Kras alleles deriving from the different parental strains (Chen et al., 1994) , although such strain-specific Kras expression was not confirmed (Jones-Bolin et al., 1998). Our model, in which the effects of the C57BL/6J and A/J genetic backgrounds on Kras gene mutation are compared in a context where the other allele is the same (A/J type at Pas1 locus) and which contains the Hras gene, enables comparison of Kras mutation frequency in a context where Hras mutations can be generated anyway. Thus, we were able to suggest cis-acting elements as the potential cause of the allele-specific Kras mutability. However, we cannot rule out the possibility that the Hras/neo cassette itself contribute to the hypermutability of the Hras-replacement gene, as it changed the local genomic sequence of the Kras locus.
Kras has been proposed as a Pas1 candidate based on the observed switch from lung tumor resistance to susceptibility of the Mus spretus-derived Pas1 allele in the Kras2 LA2 model, characterized by a high susceptibility to lung tumorigenesis due to somatic recombination and consequent activation of a mutated Kras allele . In this model, Pas1 functional activity has been attributed to as yet unidentified cis-acting Kras locus polymorphisms that affect Kras mRNA expression levels . Our analysis to test whether differential expression levels of Kras and Hras might underlie the preferential Hras mutation revealed similar specific transcript levels for both Kras and the Hrasreplacement gene in both normal lung tissue and lung tumors (Figure 3) . Thus, differential expression levels of the two genes do not explain preferential Hras mutation.
Although previous studies have not allowed discrimination between the biological functions of Kras gene mutations and the genetic role of the Pas1 locus in lung tumorigenesis, our results provide evidence that the Pas1 locus modulates susceptibility to lung tumorigenesis by controlling mutability of the Kras gene, whose activating mutations are the functional effectors of lung tumor development. As Kras mutations are observed in about 30% of human lung adenocarcinomas and because such mutations affect patients' survival (De Gregorio et al., 1998; Mascaux et al., 2005) , our results point to the need for research focused on the identification of genetic elements affecting Kras mutations in lung cancer. In light of the association of polymorphisms in the human homologous Pas1 region with survival of lung adenocarcinoma patients (Dragani et al., 2000; Manenti et al., 2006) , such identification may also be relevant to the understanding of mechanisms of human lung cancer pathogenesis.
